An adhesive composition contains a -1,3-glucan derivative obtained by introducing an acyl group into -1,3-glucan; and a terpene-based resin. An adhesive tape includes an adhesive layer formed from the adhesive composition.

The present invention concerns an improved process for biorefinery of brown macroalgae, which comprises: (a) contacting the brown macroalgae with a solvent system comprising at least 30 wt % organic solvent, to obtain extracted macroalgae as solid residue and a liquor; and (b) biorefining the extracted macroalgae. The inventors have found that the contacting of step (a) results in an efficient and cost-effective dewatering of the macroalgae, wherein up to 95 wt % of the internal moisture of the macroalgae could be lost without the need for energy-consuming drying techniques. As such, the downstream biorefinery of the extracted macroalgae is greatly facilitated.

Described herein is a beta glucan material, comprising 1,3-1,6 beta glucan, that when solubilized achieves a filterability ratio ranging from 1 to 2, preferably 1 to 1.5, and a viscosity ratio ranging from 1.5 to 4. The solubilized beta glucan materials has desired viscosity build and filterability property for EOR applications.

Therapeutic compositions and/or formulations are provided, comprising: at least one cross-linked protein matrix, wherein the at least one cross-linked protein matrix comprises at least one protein residue and at least one saccharide-containing residue, and methods of producing the same. The cross-linked protein matrix may be derived from cross-linking a full length or substantially full length protein, such as tropoelastin, elastin, albumin, collagen, collagen monomers, immunoglobulins, insulin, and/or derivatives or combinations thereof, with a saccharide containing cross-linking agent, such as a polysaccharide cross-linking agent derived from, for example, hyaluronic acid or a cellulose derivative. The therapeutic compositions may be administered topically or by injection. The present disclosure also provides methods, systems, and/or kits for the preparation and/or formulation of the compositions disclosed herein.

Provided are a -1,3-1,6-glucan powder having high solubility in water, a glucan-containing composition using the powder or the like, a method for producing the 3-1,6-glucan powder, an inclusion complex, a method for producing the inclusion complex, and a method for recovering a guest molecule. The -1,3-1,6-glucan powder has a saturation solubility in water at 25 C. of from 1.0 to 20.0 % by mass. The -1,3-1,6-glucan powder is such that in a particle size distribution of 3-1,6-glucans, determined by subjecting the -1,3-1,6-glucan powder to dynamic light scattering measurements, a particle size of a peak representing a largest volume fraction is in a range from 5 nm to 15 nm, and a volume fraction of a peak outside of the particle size range from 5 nm to 15 nm is 30 % or less of the volume fraction of the peak having the largest volume fraction.

Described herein is a flowable suspension comprising about 10-60 wt % of beta glucan with desirable swelling and dispersion properties.

Therapeutic compositions and/or formulations are provided, comprising: at least one cross-linked protein matrix, wherein the at least one cross-linked protein matrix comprises at least one protein residue and at least one saccharide-containing residue, and methods of producing the same. The cross-linked protein matrix may be derived from cross-linking a full length or substantially full length protein, such as tropoelastin, elastin, albumin, collagen, collagen monomers, immunoglobulins, insulin, and/or derivatives or combinations thereof, with a saccharide containing cross-linking agent, such as a polysaccharide cross-linking agent derived from, for example, hyaluronic acid or a cellulose derivative. The therapeutic compositions may be administered topically or by injection. The present disclosure also provides methods, systems, and/or kits for the preparation and/or formulation of the compositions disclosed herein.

Substituted scleroglucans are produced and are used in the producing drilling fluid compositions. Each of the substituted scleroglucans and combination thereof have substituent A, substituent B and substituent C, and optionally each or in combination have substituent D and substituent E. Substituent A contains in its structure a unit C(O)O, substituent B contains a unit C(O)NH, substituent C contains a unit

##STR00001##

substituent D contains an aryl group, and substituent E contains a siloxane group. The substituted scleroglucan shows tackifying performance under high temperature conditions and a reduced filtration loss.

The present invention relates to a glucan having a weight average molar mass of 15,000 to 50,000 g/mol on a single chain basis and a weight average molar mass in aqueous solution on an aggregate basis of 4 to 2010.sup.5 g/mol and existing in gel form in aqueous solution at a concentration 1% at 25 C. and neutral pH and having a melting temperature (gel to sol) of 30 to 44 C. when the glucan is dissolved in water at a concentration of 2%, methods for the production thereof, medical uses thereof, physical supports having the glucan applied thereto or impregnated thereon and in vitro methods of proliferation of skin cells which comprise contacting a population of skin cells with the glucan.

Disclosed herein is a process for reducing viscosity of an aqueous composition comprising a biopolymer, comprising: obtaining an aqueous composition comprising 1,3 beta glucan wherein the aqueous composition has an initial viscosity and heating the aqueous composition to a desired temperature, preferably in combination with a desired shear rate, to reduce viscosity by at least 50%.